文献速递肾移植

GLP-1受体激动剂用于肾移植受者

GLP-1 receptor agonists for kidney transplant recipients.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本文为叙述性综述,总结GLP-1受体激动剂在肾移植受者中应用的理论依据、临床考虑及现有证据。现有数据提示其总体耐受性良好,未明确增加移植物排斥、急性胰腺炎或免疫抑制剂相互作用风险,但证据受样本量小、随访短及选择偏倚限制。

要点

  • 肾移植受者超重/肥胖、移植后糖尿病及心血管病高发,GLP-1RA是 promising 治疗策略。
  • 现有数据未明确显示GLP-1RA增加移植物排斥、急性胰腺炎或免疫抑制剂相互作用风险。
  • 胃肠道副作用和早期停药常见,需个体化咨询和剂量滴定。

核心结论

  • 现有数据提示GLP-1RA在肾移植受者中总体耐受性良好,但证据确定性受样本量小、随访短和选择偏倚限制。

研究设计与样本

  • 叙述性综述,汇总非移植人群试验及肾移植受者中新兴的真实世界证据、回顾性和前瞻性研究。

主要发现

  • GLP-1RA在非移植人群中有血糖控制、减重及心血管和肾脏保护疗效。
  • 肾移植受者中现有数据未明确显示增加移植物排斥、急性胰腺炎或免疫抑制剂相互作用风险。
  • 胃肠道副作用和早期停药常见。

临床怎么用

  • 需个体化咨询和剂量滴定以管理胃肠道副作用和早期停药。
  • 从非移植试验(如SELECT、FLOW、SMART)外推应谨慎。
  • 应采用多学科和以患者为中心的方法指导肾移植受者中GLP-1RA的安全有效使用。

局限性

  • 现有证据受小样本量、短随访和潜在选择偏倚限制,降低安全性和有效性估计的确定性。
  • 从非移植试验外推应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin-based therapies with demonstrated efficacy in glycaemic control, weight reduction and cardiovascular and renal protection. Although data in kidney transplant recipients (KTRs) remain limited, the high prevalences of overweight and obesity, post-transplant diabetes mellitus and cardiovascular disease in this population make GLP-1RAs a promising therapeutic strategy. This narrative review outlines the rationale for their use in KTRs, drawing from recent trials in non-transplant populations and emerging real-world evidence in KTRs. We summarize key clinical considerations, including patient selection, dose escalation and monitoring strategies, as well as existing retrospective and prospective studies examining safety and efficacy in the post-transplant setting. Available data suggest that GLP-1RAs are generally well tolerated, without clear evidence of increased risk for graft rejection, acute pancreatitis or interaction with immunosuppressive agents. However, gastrointestinal side effects and early discontinuation remain common, emphasizing the need for tailored counselling and dose titration. Importantly, the current evidence is constrained by small sample sizes, short follow-up and potential selection bias; these limitations lessen the certainty of safety and effectiveness estimates. Translational inferences from non-transplant trials (e.g. SELECT, FLOW, SMART) should also be made cautiously. Future studies should investigate long-term graft outcomes, changes in body composition and optimal integration with immunosuppressive regimens. A clear research agenda prioritizing graft survival, cardiovascular and kidney outcomes, quality of life, cost-effectiveness and patient-reported outcomes-ideally via randomized, multicentre or registry-based pragmatic designs-will be critical. As GLP-1RAs become increasingly accessible and clinically relevant, a multidisciplinary and patient-centred approach is essential to guide their safe and effective use in KTRs. This narrative review provides a framework for thoughtful clinical application and highlights areas for future investigation.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Schmitz SH, Orandi BJ. GLP-1 receptor agonists for kidney transplant recipients. Nephrol Dial Transplant. 2026. PMID: 41026089. doi:10.1093/ndt/gfaf199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。